biotech
Will the FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) vote favorably (majority yes) on deramiocel (CAP-1002) for Duchenne muscular dystrophy? (July 29 2026)
EHIQ
60%
Market
—
Divergence
—
The why is Premium
The full stated basis, the stamped fact-check, what the market may be mispricing, what changed since the call opened, and what would strengthen or break the thesis — that depth is the Premium tier ($249/month).
This week's public showcase: prez 2028 ossoff →
The numbers above are always free — comprehension is never gated. The divergence is a difference of opinion, not a trade recommendation.